Developing new technologies and services to improve people’s healthier life style.
This group is working to improve medical technology by creating prototypes for smart contact lenses that can accurately measure biological markers in our eyes, nanotechnology that can potentially identify and latch onto cancer cells, wearables that can tell when those nanoparticles find the cells, and eating utensils that can help users with hand tremors or limited mobility.
Even though the human body and brain remains as a mystery, creating inherent limits for health care.
Beginning of 2012, X invested in a number of initiatives with the potential to revolutionise our knowledge, identification, and management of illnesses. They were driven by a shared insight: technical advancements like as machine learning, sensor downsizing, and wearable devices were likely to lead to breakthroughs that may one day assist health practitioners be more proactive in illness treatment. Originally known as Google Life Sciences, this group of initiatives migrated from X in 2015 to become Alphabet’s Verily Life Sciences.
Verily is using technology and data science to illnesses and other global health issues that are impeding people from living better, happier lives.
Smart contact lenses, stabilizing machines, etc.
Early illness detection is one of the most intriguing possibilities at the junction of technology, laboratory research, and medicine. The Verily team had an intuition that future medical discoveries will be driven by multidisciplinary teams that merged knowledge from biology to electrical engineering, chemistry to computer science, physics to materials design. These teams also possessed a wealth of technical knowledge and extensive experience running laboratories, developing diagnostic tools, and working in clinical settings. The goal was to act as an R&D lab for the life sciences business, bridging the gap between “Is it possible?” and “Yes, it’s conceivable.”
X’s early aim was on building smaller, smarter, non-invasive devices that may greatly simplify the monitoring and measuring of biomarkers and other health signals. One study employing tiny electronics (small chips and sensors the size of glitter) resulted in the development of a smart contact lens prototype capable of providing reliable readings of biological markers in the human eye. This study has now been expanded in conjunction with Alcon, Novartis’s eye care subsidiary.
Another X team proposed that microscopic technologies embedded within the body may be used to identify illnesses sooner. They hypothesised that nanoparticles circulating in the blood might be designed to discover and adhere to specific types of cells (such as circulating malignant tumour cells), and that a bracelet-like device worn on the outside of the body could detect and quantify the nanoparticles that reached their targets. The team at X created prototypes and conducted promising tests to generate, design, and manipulate these nanoparticles.
The team also developed on Lift ware, a set of feeding aids for those who have hand tremors or restricted hand and arm mobility. Hand motions such as how the arm twists, bends, or sudden movements has been programmed to the sensors and to the on board computers. The scientists hoped that this fundamental technology may one day be transformed into a gadget that would assist doctors in more accurately monitoring symptoms.
Tackling the biggest problems in healthcare.
Verily’s staff is eager to assist in addressing some of healthcare’s most difficult issues. They combine expertise in science, engineering, and medicine with a start-up mindset, and they work closely with partners in the healthcare and life sciences industries who are just as eager to challenge convention and relentlessly pursue new breakthroughs against common diseases and other global health problems as they are.